Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

‘DOJ preps to sue over Google’s ad tech, even without its antitrust chief’ -POLITICO

https://www.politico.com/newsletters/morning-tech/2021/09/07/doj-preps-to-sue-over-googles-ad-tech-even-without-its-antitrust-chief-797440

byBill Haddad

September 7, 2021

1 minute read

https://www.politico.com/newsletters/morning-tech/2021/09/07/doj-preps-to-sue-over-googles-ad-tech-even-without-its-antitrust-chief-797440

Lottery.com Adds William Thompson To Board; Names New Executive Positions

By Shivani Kumaresan

Today, 5:02 AM

Lottery.com Inc (NASDAQ:LTRY) has appointed Ryan Dickinson as Chief Financial Officer (CFO) and President. Ryan has served as Lottery.com’s President and Chief…

LTRY

Mizuho Maintains Buy on Rivian Automotive, Lowers Price Target to $70

By Benzinga Newsdesk

Today, 5:02 AM

Mizuho analyst Vijay Rakesh maintains Rivian Automotive (NASDAQ:RIVN) with a Buy and lowers the price target from $80 to $70.

RIVN

Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

By Vandana Singh

Today, 5:02 AM

Codexis Inc (NASDAQ:CDXS) raised its guidance for 2021 following the receipt of a binding purchase order for up to $13.9 million…

CDXS

Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program

By Vandana Singh

Today, 5:02 AM

Corvus Pharmaceuticals Inc (NASDAQ: CRVS) has shared data from the Phase 3 mupadolimab COVID-19 trial.

CRVS

‘DOJ preps to sue over Google’s ad tech, even without its antitrust chief’ -POLITICO

Related Posts

Lottery.com Adds William Thompson To Board; Names New Executive Positions

Mizuho Maintains Buy on Rivian Automotive, Lowers Price Target to $70

Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

Corvus Posts Data From Discontinued Mupadolimab COVID-19 Program